HELSINKI, Finland--(BUSINESS WIRE)--Ipsat Therapies Ltd ('Ipsat') today announces that it has recruited its first patient in a Phase IIb clinical study of its lead product P1A. The study, which is multi-centre, randomized, placebo controlled and double blinded, will further evaluate the safety and efficacy of P1A administered in combination with Ampicillin in preventing the damage to the intestinal microflora caused by the residual beta-lactam antibiotic in hospitalized patients with upper- and lower respiratory tract infections. In the previous studies performed, P1A prevented the emergence of bacterial antibiotic resistance and depletion of healthy intestinal microflora, side effects commonly associated with antibiotic treatment. An excellent safety profile was also demonstrated in all patients treated with P1A.
